

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



## Hansoh Pharmaceutical Group Company Limited

翰森製藥集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3692)

### VOLUNTARY ANNOUNCEMENT

### DRUG REGISTRATION APPROVAL OF “INEBILIZUMAB INJECTIONS”

The board of directors (the “**Board**”) of Hansoh Pharmaceutical Group Company Limited (the “**Company**” and together with its subsidiaries, the “**Group**”) is pleased to announce that “Inebilizumab Injections” (trade name: XINYUE 昕越®, the “**Product**”) has been granted drug registration approval issued by the National Medical Products Administration of the People’s Republic of China for the treatment of adult patients with neuromyelitis optica spectrum disorders (“**NMOSD**”) who are anti-aquaporin-4 immunoglobulin G seropositive (“**AQP4-IgG+**”).

On May 24, 2019, the Group obtained an exclusive license from Viela Bio, Inc., which was acquired by Horizon Therapeutics plc on March 15, 2021, to develop and commercialize the Product in designated territory (i.e. Mainland China, Hong Kong and Macau) for NMOSD as well as other designated potential indications.

The obtaining of drug registration approval of the Product will further enrich and improve the Group’s product portfolio.

#### About Inebilizumab

Inebilizumab was approved by the U.S. Food and Drug Administration (FDA) in June 2020 and by the Japanese Ministry of Health, Labour and Welfare in March 2021 as a targeted CD19 B-cell depleting antibody for adult patients with AQP4-IgG+ NMOSD. As at the date of the announcement, Inebilizumab is the only approved NMOSD therapy in the U.S. that has demonstrated a clinically relevant and durable effect on delaying worsening of disability. NMOSD is a rare, severe, autoimmune disease that attacks the optic nerve, spinal cord and brain stem, which leads to loss of vision and paralysis.

By Order of the Board  
Hansoh Pharmaceutical Group Company Limited  
Zhong Huijuan  
Chairlady

Hong Kong, March 14, 2022

*As at the date of this announcement, the Board comprises Ms. Zhong Huijuan as chairlady and executive director, Mr. Lyu Aifeng and Miss Sun Yuan as executive directors, and Mr. Lin Guoqiang, Mr. Chan Charles Sheung Wai and Ms. Yang Dongtao as independent non-executive directors.*